The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer

Abstract

Simple Summary Despite advances in treatment, the treatment outcome of pancreatic cancer still remains poor. Local progression can be a significant cause of several morbidities in pancreatic cancer, and dose escalation is needed. Stereotactic body proton beam therapy (SBPT) can give higher dose while minimizing dose at organ at risk with Bragg peak. The purpose of the present study was to investigate the feasibility of SBPT in pancreatic cancer. SBPT, administered in five fractions of a total 50-60 GyRBE, was performed mostly after induction chemotherapy. Grade 3 or higher gastroduodenal toxicities occurred in 6.1% of cases. The 2-year overall survival and local control rates were 67.6% and 73.0%. SBPT showed favourable treatment outcomes and treatment-related toxicities. It could be a promising alternative to radical surgery. Background/Purpose: This study aimed to evaluate the clinical outcomes of stereotactic body proton beam therapy (SBPT) for pancreatic cancer. Methods: This retrospective study included 49 patients who underwent SBPT for pancreatic cancer between 2017 and 2020. Survival outcomes, bowel-related toxicities, and failure patterns were analysed. SBPT was performed after induction chemotherapy in 44 (89.8%) patients. The dose-fractionation scheme included 60 gray (Gy) relative biological effectiveness (RBE) in five fractions (n = 42, 85.7%) and 50 GyRBE in five fractions (n = 7, 14.3%). The median follow-up was 16.3 months (range, 1.8-45.0 months). Results: During follow-up, the best responses were complete response, partial response, and stable disease in four (8.2%), 13 (26.5%), and 31 (63.3%) patients, respectively. The 2-year overall survival, progression-free survival, and local control (LC) rates were 67.6%, 38.0%, and 73.0%, respectively. Grade >= 3 gastroduodenal (GD) toxicity occurred in three (6.1%) patients. Among them, one patient underwent endoscopic haemostasis. The other two patients received surgical management. They were followed up without disease progression for >30 months after SBPT. Overall, there was no significant dosimetric difference between the grade >= 2 and lower toxicity groups. Conclusions: SBPT provides relatively high LC rates with acceptable toxicities in pancreatic cancer.